Immune-based Therapies for Non-small Cell Lung Cancer

被引：88

作者：

Rafei, Hind ^{[1
]}

El-Bahesh, Ehab ^{[2
]}

Finianos, Antoine ^{[3
]}

Nassereddine, Samah ^{[1
]}

Tabbara, Imad ^{[4
,5
]}

机构：

[1] Clearview Canc Inst, Huntsville, AL USA

[2] Keserwan Med Ctr, Jounieh, Lebanon

[3] Clearview Canc Inst, Huntsville, AL USA

[4] George Washington Univ, Med Fac Associates, Div Hematol Oncol, Washington, DC USA

[5] George Washington Univ, GW Canc Ctr, Washington, DC USA

来源：

ANTICANCER RESEARCH | 2017年 / 37卷 / 02期

关键词：

Non-small cell lung cancer; immunotherapy; checkpoint; inhibitors; vaccine; review; DOUBLET CHEMOTHERAPY; DOUBLE-BLIND; OPEN-LABEL; PHASE-II; 1ST-LINE CHEMOTHERAPY; MPDL3280A ANTI-PDL1; NIVOLUMAB ANTI-PD-1; PATIENTS PTS; SAFETY; NSCLC;

D O I：

10.21873/anticanres.11330

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lung cancer is the leading cause of cancerrelated death worldwide. Treatment of non-small cell lung cancer has evolved tremendously over the past decade. Specifically, immune checkpoint inhibitors have become an increasingly interesting target of pharmacological blockade. These immune inhibitors have shown promising results in front-line therapy and after failure of multiple lines, as well as in monotherapy and combination with other therapies. Vaccination in non-small cell lung cancer is also an emerging field of research that holds promising results for the future of immunotherapy in non-small cell lung cancer. This review presents a concise update on the most recent data regarding the role of checkpoint inhibitors as well as vaccination in non-small cell lung cancer.

引用

页码：377 / 387

页数：11

共 54 条

[1] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].

Akbay, Esra A. ;

Koyama, Shohei ;

Carretero, Julian ;

Altabef, Abigail ;

Tchaicha, Jeremy H. ;

Christensen, Camilla L. ;

Mikse, Oliver R. ;

Cherniack, Andrew D. ;

Beauchamp, Ellen M. ;

Pugh, Trevor J. ;

Wilkerson, Matthew D. ;

Fecci, Peter E. ;

Butaney, Mohit ;

Reibel, Jacob B. ;

Soucheray, Margaret ;

Cohoon, Travis J. ;

Janne, Pasi A. ;

Meyerson, Matthew ;

Hayes, D. Neil ;

Shapiro, Geoffrey I. ;

Shimamura, Takeshi ;

Sholl, Lynette M. ;

Rodig, Scott J. ;

Freeman, Gordon J. ;

Hammerman, Peter S. ;

Dranoff, Glenn ;

Wong, Kwok-Kin .

CANCER DISCOVERY, 2013, 3 (12) :1355-1363

[2]

[Anonymous], 2018, ANTI-CANCER DRUG, DOI [DOI 10.3322/caac.20115, DOI 10.1097/CAD.0000000000000617]

[3] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). [J].

Antonia, Scott Joseph ;

Brahmer, Julie R. ;

Gettinger, Scott N. ;

Chow, Laura Quan Man ;

Juergens, Rosalyn A. ;

Shepherd, Frances A. ;

Laurie, Scott Andrew ;

Gerber, David E. ;

Goldman, Jonathan Wade ;

Shen, Yun ;

Harbison, Christopher ;

Alaparthy, Suresh ;

Chen, Allen C. ;

Borghaei, Hossein ;

Rizvi, Naiyer A. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[4] Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial [J].

Barlesi, F. ;

Scherpereel, A. ;

Gorbunova, V. ;

Gervais, R. ;

Vikstrom, A. ;

Chouaid, C. ;

Chella, A. ;

Kim, J. H. ;

Ahn, M. J. ;

Reck, M. ;

Pazzola, A. ;

Kim, H. T. ;

Aerts, J. G. ;

Morando, C. ;

Loundou, A. ;

Groen, H. J. M. ;

Rittmeyer, A. .

ANNALS OF ONCOLOGY, 2014, 25 (05) :1044-1052

[5]

Bauer TM, 2015, J CLIN ONCOL S, V33, P3013, DOI DOI 10.1200/JC0.2015.33.15_

[6] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[7] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population [J].

Brzezianska, Ewa ;

Karbownik, Malgorzata ;

Migdalska-Sek, Monika ;

Pastuszak-Lewandoska, Dorota ;

Wloch, Jan ;

Lewinski, Andrzej .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) :26-35

[8] Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial [J].

Butts, Charles ;

Socinski, Mark A. ;

Mitchell, Paul L. ;

Thatcher, Nick ;

Havel, Libor ;

Krzakowski, Maciej ;

Nawrocki, Sergiusz ;

Ciuleanu, Tudor-Eliade ;

Bosquee, Lionel ;

Manuel Trigo, Jose ;

Spira, Alexander ;

Tremblay, Lise ;

Nyman, Jan ;

Ramlau, Rodryg ;

Wickart-Johansson, Gun ;

Ellis, Peter ;

Gladkov, Oleg ;

Pereira, Jose Rodrigues ;

Eberhardt, Wilfried Ernst Erich ;

Helwig, Christoph ;

Schroeder, Andreas ;

Shepherd, Frances A. .

LANCET ONCOLOGY, 2014, 15 (01) :59-68

[9] New strategies in immunotherapy for non-small cell lung cancer [J].

Carrizosa, Daniel R. ;

Gold, Kathryn A. .

TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (05) :553-559

[10] Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation [J].

Chen, Nan ;

Fang, Wenfeng ;

Zhan, Jianhua ;

Hong, Shaodong ;

Tang, Yanna ;

Kang, Shiyang ;

Zhang, Yaxiong ;

He, Xiaobo ;

Zhou, Ting ;

Qin, Tao ;

Huang, Yan ;

Yi, Xianping ;

Zhang, Li .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (06) :910-923

← 1 2 3 4 5 6 →